References
Bacalbasa N, Balescu I, Dima S, Brasoveanu V, Popescu I (2015)
Prognostic factors and survival in patients treated surgically for
primary and recurrent uterine leiomyosarcoma: a single center
experience. Anticancer Res 35 : 2229–2234.
Barney BM, Petersen IA, Dowdy SC, Bakkum-Gamez JN, Haddock MG (2012)
Long-term outcomes with intraoperative radiotherapy as a component of
treatment for locally advanced or recurrent uterine sarcoma. Int J
Radiat Oncol Biol Phys 83 : 191–197,
doi:10.1016/j.ijrobp.2011.06.1960.
Bartosch C, Afonso M, Pires-Luís AS, Galaghar A, Guimarães M, Antunes L,
Lopes JM (2017) Distant Metastases in Uterine Leiomyosarcomas: The Wide
Variety of Body Sites and Time Intervals to Metastatic Relapse.Int J Gynecol Pathol 36 : 31–41,
doi:10.1097/PGP.0000000000000284.
Bernstein-Molho R, Grisaro D, Soyfer V, Safra T, Merimsky O (2010)
Metastatic uterine leiomyosarcomas: a single-institution experience.Int J Gynecol Cancer 20 : 255–260,
doi:10.1111/IGC.0b013e3181c9e289.
Bizzarri N, Ghirardi V, Di Fiore GLM, De Iaco P, Gadducci A, Casarin J,
Perrone AM, Pasciuto T, Scambia G, Fagotti A (2019) Secondary
cytoreductive surgery in recurrent uterine leiomyosarcoma: a
multi-institutional study. Int J Gynecol Cancer 29 :
1134–1140, doi:10.1136/ijgc-2019-000355.
Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA,
Long Roche KC, Sonoda Y, Hensley ML, O’Cearbhaill RE, Chi DS, Alektiar
KM, Abu-Rustum NR, Leitao MM (2019) Secondary surgical resection for
patients with recurrent uterine leiomyosarcoma. Gynecol Oncol154 : 333–337, doi:10.1016/j.ygyno.2019.05.015.
Díaz-Montes TP, El-Sharkawy F, Lynam S, Harper A, Sittig M, MacDonald R,
Gushchin V, Sardi A (2018) Efficacy of Hyperthermic Intraperitoneal
Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent
Uterine Sarcoma. Int J Gynecol Cancer 28 : 1130–1137,
doi:10.1097/IGC.0000000000001289.
George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya
N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C (2014)
Phase 2 trial of aromatase inhibition with letrozole in patients with
uterine leiomyosarcomas expressing estrogen and/or progesterone
receptors. Cancer 120 : 738–743, doi:10.1002/cncr.28476.
Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS (2007) Secondary
cytoreduction in the management of recurrent uterine leiomyosarcoma.Gynecol Oncol 106 : 82–88,
doi:10.1016/j.ygyno.2007.02.031.
van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali
PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom
H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C,
Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, EORTC Soft Tissue
and Bone Sarcoma Group, PALETTE study group (2012) Pazopanib for
metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind,
placebo-controlled phase 3 trial. Lancet 379 :
1879–1886, doi:10.1016/S0140-6736(12)60651-5.
Hensley ML, Blessing JA, Mannel R, Rose PG (2008) Fixed-dose rate
gemcitabine plus docetaxel as first-line therapy for metastatic uterine
leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Gynecol Oncol 109 : 329–334,
doi:10.1016/j.ygyno.2008.03.010.
Hensley ML, Miller A, O’Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez
JN, Michael H (2015) Randomized phase III trial of gemcitabine plus
docetaxel plus bevacizumab or placebo as first-line treatment for
metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology
Group study. J Clin Oncol 33 : 1180–1185,
doi:10.1200/JCO.2014.58.3781.
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van
Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L,
Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel
JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER,
Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A (2020) Larotrectinib
in patients with TRK fusion-positive solid tumours: a pooled analysis of
three phase 1/2 clinical trials. Lancet Oncol 21 :
531–540, doi:10.1016/S1470-2045(19)30856-3.
Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B (2016) Uterine
Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology,
and End Results Database. Int J Gynecol Cancer 26 :
1098–1104, doi:10.1097/IGC.0000000000000720.
Jimenez WA, Sardi A, Nieroda C, Gushchin V (2014) Cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy in the management of
recurrent high-grade uterine sarcoma with peritoneal dissemination.Am J Obstet Gynecol 210 : 259.e1-8,
doi:10.1016/j.ajog.2013.11.002.
Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1396
patients with uterine leiomyosarcomas: emphasis on impact of
lymphadenectomy and oophorectomy. Cancer 112 : 820–830,
doi:10.1002/cncr.23245.
Kortmann B, Reimer T, Gerber B, Klautke G, Fietkau R (2006) Concurrent
radiochemotherapy of locally recurrent or advanced sarcomas of the
uterus. Strahlenther Onkol 182 : 318–324,
doi:10.1007/s00066-006-1491-2.
Kurman RJ, Carcanigiu ML, Herrington S, Young RH. World Health
Organization classification of tumours of the female reproductive
organs. IARC, Lyon, 2014.
Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D,
Venkatraman E, Alektiar K, Barakat RR (2002) Surgical resection of
pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.Gynecol Oncol 87 : 287–294, doi:10.1006/gyno.2002.6840.
Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar
CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, Symanowski JT,
Steuerwald NM, Anderson CJ, Patt JC, Kneisl JS, Kim ES (2021) Phase II
Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and
Unresectable Soft-Tissue Sarcoma. Clin Cancer Resdoi:10.1158/1078-0432.CCR-21-2001.
Mbatani N, Olawaiye AB, Prat J (2018) Uterine sarcomas. Int J
Gynaecol Obstet 143 Suppl 2 : 51–58, doi:10.1002/ijgo.12613.
Nakamura K, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sekiya R, Sakata J,
Yamamoto E, Shibata K, Kikkawa F (2018) Secondary cytoreductive surgery
potentially improves the oncological outcomes of patients with recurrent
uterine sarcomas. Mol Clin Oncol 8 : 499–503,
doi:10.3892/mco.2018.1560.
Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C,
Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F,
Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M,
Le Cesne A, Lacas B, Duffaud F, French Sarcoma Group (2015) Trabectedin
in combination with doxorubicin for first-line treatment of advanced
uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised,
multicentre, phase 2 trial. Lancet Oncol 16 : 457–464,
doi:10.1016/S1470-2045(15)70070-7.
Pedra Nobre S, Hensley ML, So M, Zhou QC, Iasonos A, Leitao MM, Ducie J,
Chiang S, Mueller JJ, Abu-Rustum NR, Zivanovic O (2021) The impact of
tumor fragmentation in patients with stage I uterine leiomyosarcoma on
patterns of recurrence and oncologic outcome. Gynecol Oncol160 : 99–105, doi:10.1016/j.ygyno.2020.10.020.
Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET,
Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J,
Johnson R, Moore R, Jones RL, Cranmer LD (2020) Assessment of
Doxorubicin and Pembrolizumab in Patients With Advanced
Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.JAMA Oncol 6 : 1778–1782,
doi:10.1001/jamaoncol.2020.3689.
Rauh-Hain JA, Hinchcliff EM, Oduyebo T, Worley MJ, Andrade CA, Schorge
JO, George S, Muto MG, del Carmen MG (2014) Clinical outcomes of women
with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol
Cancer 24 : 1434–1440, doi:10.1097/IGC.0000000000000221.
Roberts ME, Aynardi JT, Chu CS (2018) Uterine leiomyosarcoma: A review
of the literature and update on management options. Gynecol Oncol151 : 562–572, doi:10.1016/j.ygyno.2018.09.010.
Sardi A, Sipok A, Baratti D, Deraco M, Sugarbaker P, Salti G, Yonemura
Y, Sammartino P, Glehen O, Bakrin N, Díaz-Montes TP, Gushchin V (2017)
Multi-institutional study of peritoneal sarcomatosis from uterine
sarcoma treated with cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy. Eur J Surg Oncol 43 :
2170–2177, doi:10.1016/j.ejso.2017.08.011.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E,
Grignani G, Camargo V, Bauer S, Rha SY, Blay J-Y, Hohenberger P, D’Adamo
D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR (2016)
Eribulin versus dacarbazine in previously treated patients with advanced
liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre,
phase 3 trial. Lancet 387 : 1629–1637,
doi:10.1016/S0140-6736(15)01283-0.
Seagle B-LL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S
(2017) Prognosis and treatment of uterine leiomyosarcoma: A National
Cancer Database study. Gynecol Oncol 145 : 61–70,
doi:10.1016/j.ygyno.2017.02.012.
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt
C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K,
Tirabosco R, Forsyth S, Nash S, Dehbi H-M, Beare S (2017) Gemcitabine
and docetaxel versus doxorubicin as first-line treatment in previously
untreated advanced unresectable or metastatic soft-tissue sarcomas
(GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol18 : 1397–1410, doi:10.1016/S1470-2045(17)30622-8.
Stojadinovic A, Yeh A, Brennan MF (2002) Completely resected recurrent
soft tissue sarcoma: primary anatomic site governs outcomes. J Am
Coll Surg 194 : 436–447, doi:10.1016/s1072-7515(02)01120-1.
Takehara K, Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T,
Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Saito T
(2020) Clinical status and prognostic factors in Japanese patients with
uterine leiomyosarcoma. Gynecol Oncol 157 : 115–120,
doi:10.1016/j.ygyno.2020.01.022.
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D,
Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin
A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK
(2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment
of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2
trial. Lancet 388 : 488–497,
doi:10.1016/S0140-6736(16)30587-6.
Villalaín-González C, Tejerizo-García Á, Lopez-Garcia P, López-González
G, Oliver-Perez MR, Jiménez-López JS (2017) Vaginal metastasis as the
initial presentation of leiomyosarcoma: a case report. BMC Cancer17 : 503, doi:10.1186/s12885-017-3484-1.
Table 1. Clinicopathological characteristics of SCS and non-SCS
patients in the entire cohort